Intelligent Bio Solutions (NASDAQ:INBS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Intelligent Bio Solutions (NASDAQ:INBS) from a sell rating to a hold rating in a report issued on Saturday morning.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Intelligent Bio Solutions in a research report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Intelligent Bio Solutions currently has an average rating of “Sell”.

Intelligent Bio Solutions Price Performance

INBS opened at $1.07 on Friday. Intelligent Bio Solutions has a 12-month low of $1.01 and a 12-month high of $2.75. The stock has a market cap of $9.72 million, a price-to-earnings ratio of -0.52 and a beta of 4.49. The business has a 50 day moving average of $1.43 and a 200-day moving average of $1.50.

Intelligent Bio Solutions (NASDAQ:INBS) last released its quarterly earnings data on Friday, August 15th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.25). Intelligent Bio Solutions had a negative net margin of 346.22% and a negative return on equity of 231.13%. The business had revenue of $0.84 million during the quarter, compared to analyst estimates of $4.30 million. As a group, analysts expect that Intelligent Bio Solutions will post -1.25 earnings per share for the current year.

Hedge Funds Weigh In On Intelligent Bio Solutions

A hedge fund recently bought a new stake in Intelligent Bio Solutions stock. Altium Capital Management LLC bought a new position in shares of Intelligent Bio Solutions Inc. (NASDAQ:INBS) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 149,252 shares of the company’s stock, valued at approximately $215,000. Intelligent Bio Solutions accounts for approximately 0.5% of Altium Capital Management LLC’s investment portfolio, making the stock its 17th largest holding. Altium Capital Management LLC owned 2.19% of Intelligent Bio Solutions as of its most recent filing with the Securities & Exchange Commission. 32.97% of the stock is currently owned by institutional investors.

About Intelligent Bio Solutions

Intelligent Bio Solutions Inc, a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities.